Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $60.00 short call and a strike $65.00 long call offers a potential 9.17% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $60.00 by expiration. The full premium credit of $0.42 would be kept by the premium seller. The risk of $4.58 would be incurred if the stock rose above the $65.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 47.18 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Eli Lilly and Company Launches Second Education Program for Medical Students
Fri, 25 Apr 2014 12:00:00 GMT
PR Newswire – INDIANAPOLIS, April 25, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) announced today the launch of another medical student education program, an internship for aspiring physicians. The Lilly Medical Student Intern Program, the second phase of its medical student programs, offers opportunities for medical students between their first and second years to work alongside healthcare professionals in the pharmaceutical industry to gain scientific knowledge and experience in several areas, including preclinical research, clinical trial development, medical affairs, regulatory affairs, bio-ethics and patient safety. Six students from Marian University College of Osteopathic Medicine will be the first to participate in the intern program at Eli Lilly and Company's Indianapolis headquarters. “We see a great synergy in the making, as these students will have the opportunity to obtain unique, real-world experiences in the realm of drug discovery and development and the myriad of regulatory, legal and business aspects of the pharmaceutical industry,” said Dr. Bryan Larsen, Ph.D., associate dean for biomedical sciences, Marian University College of Osteopathic Medicine.
[$$] Takeda May Not Cover Lilly's Share of Diabetes-Drug Lawsuit
Thu, 24 Apr 2014 18:39:29 GMT
Eli Lilly Jr. Made His Firm A Pharmaceutical Power
Thu, 24 Apr 2014 17:30:00 GMT
Eli Lilly Q1 Earnings In-Line, Revenues Miss
Thu, 24 Apr 2014 16:50:05 GMT
New drug sales help boost Novartis Q1 profit
Thu, 24 Apr 2014 16:46:46 GMT
Also on Market Tamer…
Follow Us on Facebook